A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery

Asadzadeh, Zahra; Derakhshani, Afshin; Hosseinkhani, Negar; Mokhtarzadeh, Ahad; Baghbanzadeh, Amir; Hajiasgharzadeh, Khalil; Brunetti, Oronzo; Argentiero, Antonella; Racanelli, Vito; Silvestris, Nicola; Baradaran, Behzad

doi:10.1016/j.biopha.2021.112213

Cited by 24 publications

(17 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-200 family miRNAs have been shown to target PD-L1 [ 121 , 122 , 123 ]. The combination of miR-200 family miRNA-mimics and immune checkpoint inhibitors might enhance the therapeutic potential of immune checkpoint inhibitors.…”

Section: Discussionmentioning

confidence: 99%

“…Immune checkpoint molecules such as programmed death ligand-1 (PD-L1) and PD-1 are known as targets for anti-cancer drug development [ 121 ]. Figure 4 C shows the regulation of PD-L1 expression by the miR-200 family.…”

Section: Role Of the Mir-200 Family In Anti-cancer Drug Resistancementioning

confidence: 99%

“…Figure 4 C shows the regulation of PD-L1 expression by the miR-200 family. miR-200a-3p and miR-200c-3p decreased the expression of PD-L1, suppressed the development of colorectal cancer, and promoted anti-cancer immune responses [ 121 ]. miR-429 directly targeted PD-L1 and suppressed gastric cancer cell proliferation [ 122 ].…”

Section: Role Of the Mir-200 Family In Anti-cancer Drug Resistancementioning

confidence: 99%

See 2 more Smart Citations

Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics

Shim

Jeoung

2022

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small non-coding RNAs (18–24 nucleotides) that play significant roles in cell proliferation, development, invasion, cancer development, cancer progression, and anti-cancer drug resistance. miRNAs target multiple genes and play diverse roles. miRNAs can bind to the 3′UTR of target genes and inhibit translation or promote the degradation of target genes. miR-200 family miRNAs mostly act as tumor suppressors and are commonly decreased in cancer. The miR-200 family has been reported as a valuable diagnostic and prognostic marker. This review discusses the clinical value of the miR-200 family, focusing on the role of the miR-200 family in the development of cancer and anti-cancer drug resistance. This review also provides an overview of the factors that regulate the expression of the miR-200 family, targets of miR-200 family miRNAs, and the mechanism of anti-cancer drug resistance regulated by the miR-200 family.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Role Of the Mir-200 Family In Anti-cancer Drug Resistancementioning

confidence: 99%

Section: Role Of the Mir-200 Family In Anti-cancer Drug Resistancementioning

confidence: 99%

See 1 more Smart Citation

Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics

Shim

Jeoung

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…11,12 miRNAs affect cell proliferation, differentiation, and apoptosis by regulating activation and expression of critical signaling molecules such as transcription factors, cytokines, growth factors, pro-apoptotic mediators, and anti-apoptotic mediators. [13][14][15] Recently, dysregulation of miRNA expression has been identified to play an important role in progression and metastasis of CRC. 16 The first report of a role for miRNAs in colon cancer was the downregulation of miR-143 and miR-145, 17 which leads to the development of cancer through EGFP signaling.…”

Section: Introductionmentioning

confidence: 99%

<em>miR-19a</em> targeting <em>CLCA4</em> to regulate the proliferation, migration, and invasion of colorectal cancer cells

Huang

2022

Eur J Histochem

View full text Add to dashboard Cite

The role of miR-19a in colorectal cancer (CRC), a devastating disease with high mortality and morbidity, remains controversial. In the present study, we show that the level of miR-19a is significantly higher in clinical CRC tissue samples than in paracancerous tissue samples, and significantly higher in CRC cells lines HT29, SW480, and CaCO2 than in the normal human colon mucosal epithelial cell line NCM460. miR-19a mimics and inhibitors were synthesized and validated. Overexpression of miR-19a mimics significantly promoted, while miR-19a inhibitors inhibited, the proliferation, survival, migration, and invasion of SW480 and CaCO2 CRC cells. Furthermore, mRNA and protein levels of chloride channel accessory 4 (CLCA4) were lower in CRC cells and tissues. Bioinformatics and a luciferase reporter assay confirmed that CLCA4 was a miR-19a target. Further, miR-19a inhibition increased CLCA4 expression. The inhibitory effect of miR-19a on cell growth, survival, migration, and invasion was reversed by knockdown of CLCA4 expression. The data demonstrated that the miR-19a/CLCA4 axis modulates phospho-activation of the PI3K/AKT pathway in CRC cells. In conclusion, our results revealed that miR-19a overexpression decreases CLCA4 levels to promote CRC oncogenesis, suggesting that miR-19a inhibitors have potential applications for future therapeutic of CRC.

show abstract

“…The PD-1/programmed death-ligand 1 (PD-L1) inhibitory axis has been one of the well-studied inhibitory immune checkpoint axes in cancers; thus, targeting this axis via monoclonal antibodies was among the attempts to stimulate anti-tumoral immune responses [7]. This axis can be established between immune and tumor cells and can substantially contribute to immunosuppressive tumor microenvironment development [8]. Although monoclonal antibodies targeting this inhibitory axis have been promising for some solid cancers, like triple-negative breast cancer, they have not yielded meaningful results in other solid cancers, like glioblastoma [9,10].…”

Section: Introductionmentioning

confidence: 99%

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers

Hosseinkhani

Baradaran

Jafarabadi

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Preclinical studies have indicated that T-cell immunoglobulin and ITIM domain (TIGIT) can substantially attenuate anti-tumoral immune responses. Although multiple clinical studies have evaluated the significance of TIGIT in patients with solid cancers, their results remain inconclusive. Thus, we conducted the current systematic review and meta-analysis based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) to determine its significance in patients with solid cancers. We systematically searched the Web of Science, Embase, PubMed, and Scopus databases to obtain peer-reviewed studies published before September 20, 2020. Our results have shown that increased TIGIT expression has been significantly associated with inferior overall survival (OS) (HR = 1.42, 95% CI: 1.11–1.82, and p-value = 0.01). Besides, the level of tumor-infiltrating TIGIT+CD8+ T-cells have been remarkably associated inferior OS and relapse-free survival (RFS) of affected patients (HR = 2.17, 95% CI: 1.43–3.29, and p-value < 0.001, and HR = 1.89, 95% CI: 1.36–2.63, and p-value < 0.001, respectively). Also, there is a strong positive association between TIGIT expression with programmed cell death-1 (PD-1) expression in these patients (OR = 1.71, 95% CI: 1.10–2.68, and p-value = 0.02). In summary, increased TIGIT expression and increased infiltration of TIGIT+CD8+ T-cells can substantially worsen the prognosis of patients with solid cancers. Besides, concerning the observed strong association between TIGIT and PD-1, ongoing clinical trials, and promising preclinical results, PD-1/TIGIT dual blockade can potentially help overcome the immune-resistance state seen following monotherapy with a single immune checkpoint inhibitor in patients with solid cancers.

show abstract

A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery

Cited by 24 publications

References 121 publications

Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics

Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics

<em>miR-19a</em> targeting <em>CLCA4</em> to regulate the proliferation, migration, and invasion of colorectal cancer cells

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers

Contact Info

Product

Resources

About